Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform
- 1 November 2018
- journal article
- review article
- Published by Elsevier in Neurochemistry International
- Vol. 120, 99-111
Abstract
No abstract availableKeywords
Funding Information
- Canada Research Chair
This publication has 196 references indexed in Scilit:
- Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndromeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Influence of pH on the speciation of copper(II) in reactions with the green tea polyphenols, epigallocatechin gallate and gallic acidJournal of Inorganic Biochemistry, 2012
- Morin attenuates tau hyperphosphorylation by inhibiting GSK3βNeurobiology of Disease, 2011
- Mechanisms Underlying Inflammation in NeurodegenerationCell, 2010
- Drug development for Alzheimer's disease: Where are we now and where are we headed?The American Journal of Geriatric Pharmacotherapy, 2009
- Protective effect of quercetin in primary neurons against Aβ(1–42): relevance to Alzheimer's diseaseThe Journal of Nutritional Biochemistry, 2009
- Anti-Inflammatory Effects of Sinapic Acid through the Suppression of Inducible Nitric Oxide Synthase, Cyclooxygase-2, and Proinflammatory Cytokines Expressions via Nuclear Factor-κB InactivationJournal of Agricultural and Food Chemistry, 2008
- Role of Bax in quercetin-induced apoptosis in human prostate cancer cellsBiochemical Pharmacology, 2008
- Epigallocatechin gallate (EGCG) potentiates the cytotoxicity of rotenone in neuroblastoma SH-SY5Y cellsBrain Research, 2007
- A tale of two mitochondrial channels, MAC and PTP, in apoptosisApoptosis, 2007